Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Neurocrine Biosciences
(NASDAQ:NBIX)
Intraday
$138.97
-1.12
[-0.80%]
After-Hours
$138.97
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$138.97
-1.12
[-0.80%]
At close: Apr 24
$138.97
0
[0.00%]
After Hours: 4:20PM EDT
Get Report
Watch
Q1 2024 Earnings in 6 days from now on Wed May 1st, before the market open
Conference call scheduled in 6 days at 8:00 AM
Click to view the webcast
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Neurocrine Biosciences Stock (NASDAQ:NBIX)
Neurocrine Biosciences Stock (NASDAQ: NBIX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, April 24, 2024
Wells Fargo Upgrades Neurocrine Biosciences to Overweight, Raises Price Target to $170
Benzinga Newsdesk
-
16 hours ago
Oppenheimer Maintains Outperform on Neurocrine Biosciences, Maintains $200 Price Target
Benzinga Newsdesk
-
19 hours ago
HC Wainwright & Co. Reiterates Buy on Neurocrine Biosciences, Maintains $150 Price Target
Benzinga Newsdesk
-
20 hours ago
Tuesday, April 23, 2024
Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder
Vandana Singh
-
1 day ago
Needham Reiterates Hold on Neurocrine Biosciences
Benzinga Newsdesk
-
1 day ago
Neurocrine Biosciences shares are trading higher after the company's Phase 2 SAVITRI study met its primary endpoint in major depressive disorder.
Benzinga Newsdesk
-
1 day ago
Neurocrine Biosciences Says Phase 2 SAVITRI Study Met Primary Endpoint For Adults With Major Depressive Disorder
Benzinga Newsdesk
-
1 day ago
Wednesday, April 17, 2024
Wedbush Reiterates Outperform on Neurocrine Biosciences, Maintains $147 Price Target
Benzinga Newsdesk
-
Apr 17, 2024, 1:19PM
Tuesday, April 16, 2024
Sentia Medical Sciences Further Extends Research Collaboration With Neurocrine Biosciences To Discover Novel CRF Peptides
Benzinga Newsdesk
-
Apr 16, 2024, 4:02PM
Selection Of The Development Candidate Triggered A $3M Milestone Payment To Voyager, Which The Company Expects To Receive In Q2 Of 2024
Benzinga Newsdesk
-
Apr 16, 2024, 7:12AM
Voyager Therapeutics And Neurocrine Biosciences Expect To File An FDA Investigational New Drug Application For GBA1 Program Candidate In 2025
Benzinga Newsdesk
-
Apr 16, 2024, 7:07AM
Voyager Therapeutics And Neurocrine Biosciences Have Selected Lead Development Candidate In GBA1 Gene Therapy Program For Potential Treatment Of Parkinson's Disease And Other GBA1-mediated Diseases
Benzinga Newsdesk
-
Apr 16, 2024, 7:06AM
Nxera Pharma's NBI-1117568, Backed by Neurocrine Biosciences, Successfully Completes Long-Term Preclinical Toxicity Program
Benzinga Newsdesk
-
Apr 16, 2024, 3:46AM
Wednesday, April 10, 2024
Where Neurocrine Biosciences Stands With Analysts
Benzinga Insights
-
Apr 10, 2024, 11:00AM
Cantor Fitzgerald Reiterates Overweight on Neurocrine Biosciences, Maintains $155 Price Target
Benzinga Newsdesk
-
Apr 10, 2024, 9:45AM
Wednesday, April 03, 2024
Neurocrine Biosciences Announces First-Patient Dosed In Phase 2 Clinical Study Evaluating NBI-1070770 In Adults With Major Depressive Disorder
Benzinga Newsdesk
-
Apr 3, 2024, 8:32AM
Thursday, March 28, 2024
Neurocrine Biosciences Announces Initiation Of Phase 1 Clinical Study Evaluating Effects Of NBI-1065890, A Second-Generation VMAT2 Inhibitor, In Healthy Adults
Benzinga Newsdesk
-
Mar 28, 2024, 8:34AM
Thursday, March 21, 2024
Watching Neurocrine Biosciences; Shares Move Higher As Traders Circulate Stock Picked By Investor Business Daily SwingTrader
Benzinga Newsdesk
-
Mar 21, 2024, 10:00AM
Wednesday, March 20, 2024
JP Morgan Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $158
Benzinga Newsdesk
-
Mar 20, 2024, 8:04AM
Tuesday, March 19, 2024
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
Vandana Singh
-
Mar 19, 2024, 2:16PM
Wednesday, March 13, 2024
In-Depth Examination Of 8 Analyst Recommendations For Neurocrine Biosciences
Benzinga Insights
-
Mar 13, 2024, 4:00PM
Decoding 8 Analyst Evaluations For Neurocrine Biosciences
Benzinga Insights
-
Mar 13, 2024, 10:03AM
Oppenheimer Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $200
Benzinga Newsdesk
-
Mar 13, 2024, 8:38AM
Monday, February 26, 2024
Selection Of The Development Candidate For Friedreich's Ataxia in Collaboration with Neurocrine Biosciences Triggered $5M Milestone Payment To Voyager, Which It Expects To Receive In The First Quarter Of 2024
Benzinga Newsdesk
-
Feb 26, 2024, 7:14AM
Voyager Therapeutics Announced That The Joint Steering Committee With Its Collaborator Neurocrine Biosciences Has Selected A Lead Development Candidate In Friedreich's Ataxia Program. The Companies Expect The Program To Advance Into Human Trials In 2025
Benzinga Newsdesk
-
Feb 26, 2024, 7:12AM
Thursday, February 15, 2024
CHARLES KEVIN GORMAN At Neurocrine Biosciences Decides to Exercises Options Worth $470K
Benzinga Insights
-
Feb 15, 2024, 10:01AM
Monday, February 12, 2024
Why This Teva Pharmaceutical Analyst Is Turning Bullish On The Austedo Franchise
Priya Nigam
-
Feb 12, 2024, 11:53AM
Thursday, February 08, 2024
Citigroup Maintains Neutral on Neurocrine Biosciences, Lowers Price Target to $140
Benzinga Newsdesk
-
Feb 8, 2024, 11:25AM
Mizuho Maintains Neutral on Neurocrine Biosciences, Raises Price Target to $140-Report released on 7th February 2024
Benzinga Newsdesk
-
Feb 8, 2024, 10:29AM
Breaking Down Neurocrine Biosciences: 8 Analysts Share Their Views
Benzinga Insights
-
Feb 8, 2024, 9:00AM
Wells Fargo Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $140
Benzinga Newsdesk
-
Feb 8, 2024, 8:42AM
Wednesday, February 07, 2024
Neurocrine Biosciences Forecasts Ingrezza (Valbenazine) Full Year 2024 Net Product Sales Guidance Of $2.1B-$2.2B
Benzinga Newsdesk
-
Feb 7, 2024, 7:07AM
Neurocrine Biosciences Reports Ingrezza (valbenazine) Q4 And FY23 Net Product Sales Of $500M And $1.84B, Representing YoY Growth of 25% and 29% Respectively
Benzinga Newsdesk
-
Feb 7, 2024, 7:06AM
Neurocrine Biosciences Q4 Adjusted EPS $1.54 Beats $1.15 Estimate, Sales $515.20M Miss $518.13M Estimate
Benzinga Newsdesk
-
Feb 7, 2024, 7:04AM
Earnings Scheduled For February 7, 2024
Benzinga Insights
-
Feb 7, 2024, 5:13AM
Tuesday, February 06, 2024
Earnings Outlook For Neurocrine Biosciences
Benzinga Insights
-
Feb 6, 2024, 9:02AM
Thursday, January 25, 2024
Goldman Sachs Maintains Buy on Neurocrine Biosciences, Raises Price Target to $153
Benzinga Newsdesk
-
Jan 25, 2024, 9:16AM
Tuesday, January 23, 2024
Unveiling 13 Analyst Insights On Neurocrine Biosciences
Benzinga Insights
-
Jan 23, 2024, 10:00AM
Barclays Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $150
Benzinga Newsdesk
-
Jan 23, 2024, 8:20AM
Monday, December 18, 2023
Stifel Maintains Buy on Neurocrine Biosciences, Raises Price Target to $144
Benzinga Newsdesk
-
Dec 18, 2023, 10:38AM
Wednesday, December 13, 2023
Wells Fargo Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $127
Benzinga Newsdesk
-
Dec 13, 2023, 10:17AM
Citigroup Initiates Coverage On Neurocrine Biosciences with Neutral Rating, Announces Price Target of $127
Benzinga Newsdesk
-
Dec 13, 2023, 4:46AM
Tuesday, December 12, 2023
Deutsche Bank Initiates Coverage On Neurocrine Biosciences with Buy Rating, Announces Price Target of $136
Benzinga Newsdesk
-
Dec 12, 2023, 5:10AM
Thursday, December 07, 2023
Analyst Expectations for Neurocrine Biosciences's Future
Benzinga Insights
-
Dec 7, 2023, 11:00AM
Canaccord Genuity Reiterates Buy on Neurocrine Biosciences, Maintains $150 Price Target
Benzinga Newsdesk
-
Dec 7, 2023, 10:50AM
Wednesday, December 06, 2023
Sosei Heptares' Partner Neurocrine Biosciences Confirms its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical Studies
Benzinga Newsdesk
-
Dec 6, 2023, 3:03AM
Tuesday, December 05, 2023
Neurocrine Biosciences Gets Breakthrough Therapy Designation From FDA For Crinecerfont In Congenital Adrenal Hyperplasia
Benzinga Newsdesk
-
Dec 5, 2023, 4:04PM
Friday, November 10, 2023
BMO Capital Maintains Market Perform on Neurocrine Biosciences, Lowers Price Target to $100
Benzinga Newsdesk
-
Nov 10, 2023, 3:12PM
RBC Capital Maintains Sector Perform on Neurocrine Biosciences, Lowers Price Target to $121
Benzinga Newsdesk
-
Nov 10, 2023, 2:20PM
Why Is Neurocrine Biosciences Stock Trading Lower Today?
Vandana Singh
-
Nov 10, 2023, 1:43PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch